DGIdb - BROMOCRIPTINE Drug Record

BROMOCRIPTINE chembl:CHEMBL493 Approved

Alternate Names:

BROMOCRIPTINE
SANDOZ 15-754
PARLODEL
CB-154
2-BROMOERGOCRYPTINE
PLO154
2-BROMO-Α-ERGOKRYPTINE
2-BROMO-ALPHA-ERGOKRYPTIN
BROMOCRYPTINE
2-BROMO-Α-ERGOCRYPTINE
BROMOCRIPTINA
2-BROMO-ALPHA-ERGOKRYPTINE
PARLODEL®
(5'ALPHA)-2-BROMO-12'-HYDROXY-2'-(1-METHYLETHYL)-5'-(2-METHYLPROPYL)-3',6',18-TRIOXOERGOTAMAN
2-BROMO-Α-ERGOKRYPTIN
BROMOERGOCRYPTINE
BROMOERGOCRIPTINE
(5'ALPHA)-2-BROMO-12'-HYDROXY-5'-ISOBUTYL-2'-ISOPROPYL-3',6',18-TRIOXOERGOTAMAN
2-BROMO-ALPHA-ERGOCRYPTINE
BROMOCRIPTINUM
(5'ALPHA)-2-BROMO-12'-HYDROXY-2'-(1-METHYLETHYL)-5'-(2-METHYLPROPYL)ERGOTAMAN-3',6',18-TRIONE
drugbank:01200
chemidplus:25614-03-3
pubchem.compound:31101
rxcui:1760
chembl:CHEMBL493

Drug Info:

Drug Class	antiparkinson agents
Year of Approval	1978
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antidiabetic
Drug Categories	anti-parkinson drugs
Drug Categories	adrenergic agonists
Drug Categories	adrenergic alpha-1 receptor agonists
Drug Categories	adrenergic alpha-1 receptor antagonists
Drug Categories	adrenergic alpha-2 receptor agonists
Drug Categories	adrenergic alpha-agonists
Drug Categories	adrenergic alpha-antagonists
Drug Categories	adrenergic antagonists
Drug Categories	agents producing tachycardia
Drug Categories	agents that produce hypertension
Drug Categories	antidepressive agents
Drug Categories	central nervous system depressants
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 inhibitors
Drug Categories	cytochrome p-450 cyp3a4 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	ergot alkaloids and derivatives
Drug Categories	ergot-derivative dopamine receptor agonists
Drug Categories	genito urinary system and sex hormones
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	p-glycoprotein inhibitors
Drug Categories	p-glycoprotein substrates
Drug Categories	prolactine inhibitors
Drug Categories	serotonin 5-ht2 receptor agonists
Drug Categories	serotonin agents
Drug Categories	serotonin receptor agonists

(4 More Sources)

Publications:

Doknic et al., 2002, Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine., Eur. J. Endocrinol.
Figueroa et al., 1993, [Pharmacological modification of prolactinemia. Effects on cellular immune function in normal subjects]., Rev Med Chil
Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem
Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy
Palestine et al., 1987, Bromocriptine and low dose cyclosporine in the treatment of experimental autoimmune uveitis in the rat., J. Clin. Invest.
de Leeuw van Weenen et al., 2010, The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells., Biochem. Pharmacol.
Cussac et al., 2008, Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells., Eur. J. Pharmacol.
Burdman et al., 2001, Bromocriptine and the expression of c-myc and c-fos in human prolactinomas., Neurol. Res.
Pelletier et al., 1991, Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus., Neurosci. Lett.
Knight et al., 2009, Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists., Mol. Pharmacol.
Orlowski et al., 1998, Bromocriptine modulates P-glycoprotein function., Biochem. Biophys. Res. Commun.
Shiraki et al., 2002, Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells., Jpn. J. Cancer Res.
Gibson A et al., 1979, The effects of bromocriptine on pre-synaptic and post-synaptic alpha-adrenoceptors in the mouse vas deferens., J Pharm Pharmacol
Lim et al., 2008, Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage., Pharmacol. Res.
Cavallotti et al., Age-related changes in dopamine D2 receptors in rat heart and coronary vessels., Clin. Exp. Pharmacol. Physiol.
Lahlou, 1999, Cardiovascular responses to intrathecal dopamine receptor agonists in conscious DOCA-salt hypertensive rats., Fundam Clin Pharmacol
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Lahlou et al., 2003, Blunted central bromocriptine-induced tachycardia in conscious, malnourished rats., Pharmacol. Toxicol.
Stefaneanu et al., 2001, Dopamine D2 receptor gene expression in human adenohypophysial adenomas., Endocrine
Lahlou et al., 2000, Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats., Can. J. Physiol. Pharmacol.
Ohta et al., 2003, Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes., Life Sci.
Wynalda et al., 1997, Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen., Drug Metab. Dispos.

BROMOCRIPTINE DRD3

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Partial agonist

Publications:

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy
BROMOCRIPTINE DRD4

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Specific Action of the Ligand Antagonist

Endogenous Drug? False

Direct Interaction? True

Publications:

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem
BROMOCRIPTINE HTR6

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Publications:
BROMOCRIPTINE DRD5

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Publications:

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem
BROMOCRIPTINE ADRA1D

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Publications:

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

BROMOCRIPTINE ADRA2B

Interaction Types & Directionality:

antagonist (inhibitory)

agonist (activating)

Interaction Info:

Endogenous Drug? False

Specific Action of the Ligand Antagonist

Publications:

de Leeuw van Weenen et al., 2010, The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells., Biochem. Pharmacol.

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

BROMOCRIPTINE DRD1

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Partial agonist

Endogenous Drug? False

Publications:

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

BROMOCRIPTINE HTR2C

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Partial agonist

Endogenous Drug? False

Publications:

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

Cussac et al., 2008, Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells., Eur. J. Pharmacol.

BROMOCRIPTINE HTR1D

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Partial agonist

Endogenous Drug? False

Publications:

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

BROMOCRIPTINE HTR2A

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Partial agonist

Endogenous Drug? False

Publications:

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

Cussac et al., 2008, Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells., Eur. J. Pharmacol.

BROMOCRIPTINE HTR7

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Knight et al., 2009, Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists., Mol. Pharmacol.

BROMOCRIPTINE ADRA1A

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Publications:

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

Gibson A et al., 1979, The effects of bromocriptine on pre-synaptic and post-synaptic alpha-adrenoceptors in the mouse vas deferens., J Pharm Pharmacol

BROMOCRIPTINE HTR2B

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Specific Action of the Ligand Antagonist

Endogenous Drug? False

Publications:

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

Cussac et al., 2008, Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells., Eur. J. Pharmacol.

BROMOCRIPTINE ADRA2C

Interaction Types & Directionality:

antagonist (inhibitory)

agonist (activating)

Interaction Info:

Specific Action of the Ligand Antagonist

Endogenous Drug? False

Publications:

de Leeuw van Weenen et al., 2010, The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells., Biochem. Pharmacol.

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

BROMOCRIPTINE ADRA1B

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Publications:

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

Gibson A et al., 1979, The effects of bromocriptine on pre-synaptic and post-synaptic alpha-adrenoceptors in the mouse vas deferens., J Pharm Pharmacol

BROMOCRIPTINE DRD2

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name bromocriptine mesylate,Cycloset, Ergoset

Novel drug target Established target

Specific Action of the Ligand Full agonist

Publications:

Cavallotti et al., Age-related changes in dopamine D2 receptors in rat heart and coronary vessels., Clin. Exp. Pharmacol. Physiol.

Lahlou, 1999, Cardiovascular responses to intrathecal dopamine receptor agonists in conscious DOCA-salt hypertensive rats., Fundam Clin Pharmacol

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

BROMOCRIPTINE HTR1B

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Partial agonist

Endogenous Drug? False

Publications:

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy
BROMOCRIPTINE HTR1A

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Partial agonist

Endogenous Drug? False

Publications:

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

BROMOCRIPTINE ADRA2A

Interaction Types & Directionality:

antagonist (inhibitory)

agonist (activating)

Interaction Info:

Specific Action of the Ligand Antagonist

Endogenous Drug? False

Publications:

de Leeuw van Weenen et al., 2010, The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells., Biochem. Pharmacol.

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

BROMOCRIPTINE LEP

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Doknic et al., 2002, Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine., Eur. J. Endocrinol.
BROMOCRIPTINE IL2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Figueroa et al., 1993, [Pharmacological modification of prolactinemia. Effects on cellular immune function in normal subjects]., Rev Med Chil
BROMOCRIPTINE SAG

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Palestine et al., 1987, Bromocriptine and low dose cyclosporine in the treatment of experimental autoimmune uveitis in the rat., J. Clin. Invest.
BROMOCRIPTINE MYC

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Burdman et al., 2001, Bromocriptine and the expression of c-myc and c-fos in human prolactinomas., Neurol. Res.
BROMOCRIPTINE NPY

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Pelletier et al., 1991, Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus., Neurosci. Lett.

BROMOCRIPTINE ABCB1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Orlowski et al., 1998, Bromocriptine modulates P-glycoprotein function., Biochem. Biophys. Res. Commun.

Shiraki et al., 2002, Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells., Jpn. J. Cancer Res.

BROMOCRIPTINE NFE2L2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Lim et al., 2008, Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage., Pharmacol. Res.
BROMOCRIPTINE GDNF

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Ohta et al., 2003, Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes., Life Sci.

BROMOCRIPTINE CYP1A2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Wynalda et al., 1997, Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen., Drug Metab. Dispos.

BROMOCRIPTINE FOS

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Burdman et al., 2001, Bromocriptine and the expression of c-myc and c-fos in human prolactinomas., Neurol. Res.
BROMOCRIPTINE VDR

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
BROMOCRIPTINE EHMT2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
BROMOCRIPTINE AR

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

DrugBank: DB01200

Version: 5.1.7

Alternate Names:

BROMOCRIPTINE DrugBank Drug Name

25614-03-3 CAS Number

Apo-Bromocriptine Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

de Leeuw van Weenen et al., 2010, The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells., Biochem. Pharmacol.

TEND: BROMOCRIPTINE
- Version: 01-August-2011
Alternate Names:

BROMOCRIPTINE Primary Drug Name

Drug Info:

Year of Approval 1978

Drug Class antiparkinson agents

Publications:
TdgClinicalTrial: BROMOCRIPTINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antidiabetic

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: BROMOCRIPTINE

Version: 14-September-2017

Alternate Names:

C317 NCI drug code

Drug Info:

Publications:

Ohta et al., 2003, Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes., Life Sci.

Wynalda et al., 1997, Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen., Drug Metab. Dispos.

Figueroa et al., 1993, [Pharmacological modification of prolactinemia. Effects on cellular immune function in normal subjects]., Rev Med Chil

DTC: BROMOCRIPTINE
- Version: 02-September-2020
Alternate Names:

CHEMBL493 ChEMBL Drug ID

Drug Info:

Publications:
TTD: Bromocriptine
- Version: 2020.06.01
Alternate Names:

D06YFA TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 135650026
- Version: 29-September-2020
Alternate Names:

BROMOCRIPTINE GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL493
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Direct Interaction?	True
Endogenous Drug?	False
Specific Action of the Ligand	Partial agonist

Specific Action of the Ligand	Antagonist
Endogenous Drug?	False
Direct Interaction?	True

Specific Action of the Ligand	Full agonist
Endogenous Drug?	False

Trial Name	bromocriptine mesylate,Cycloset, Ergoset
Novel drug target	Established target
Specific Action of the Ligand	Full agonist

BROMOCRIPTINE	DrugBank Drug Name
25614-03-3	CAS Number
Apo-Bromocriptine	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

BROMOCRIPTINE Drug Record

BROMOCRIPTINE chembl:CHEMBL493 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: agonist (activating)

Interaction Info: Direct Interaction? True Endogenous Drug? False Specific Action of the Ligand Partial agonist

Publications: Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Specific Action of the Ligand Antagonist Endogenous Drug? False Direct Interaction? True

Publications: Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Interaction Types & Directionality: agonist (activating)

Interaction Info: Specific Action of the Ligand Full agonist Endogenous Drug? False

Publications:

Interaction Types & Directionality: agonist (activating)

Interaction Info: Specific Action of the Ligand Full agonist Endogenous Drug? False

Publications: Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Interaction Types & Directionality: agonist (activating)

Interaction Info:

Publications: Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

Interaction Types & Directionality: antagonist (inhibitory) agonist (activating)

Interaction Info: Endogenous Drug? False Specific Action of the Ligand Antagonist

Interaction Types & Directionality: agonist (activating)

Interaction Info: Specific Action of the Ligand Partial agonist Endogenous Drug? False

Publications: Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Interaction Types & Directionality: agonist (activating)

Interaction Info: Specific Action of the Ligand Partial agonist Endogenous Drug? False

Interaction Types & Directionality: agonist (activating)

Interaction Info: Specific Action of the Ligand Partial agonist Endogenous Drug? False

Publications: Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

Interaction Types & Directionality: agonist (activating)

Interaction Info: Specific Action of the Ligand Partial agonist Endogenous Drug? False

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications: Knight et al., 2009, Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists., Mol. Pharmacol.

Interaction Types & Directionality: agonist (activating) antagonist (inhibitory)

Interaction Info:

Publications: Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy Gibson A et al., 1979, The effects of bromocriptine on pre-synaptic and post-synaptic alpha-adrenoceptors in the mouse vas deferens., J Pharm Pharmacol

Interaction Types & Directionality: agonist (activating) antagonist (inhibitory)

Interaction Info: Specific Action of the Ligand Antagonist Endogenous Drug? False

Interaction Types & Directionality: antagonist (inhibitory) agonist (activating)

Interaction Info: Specific Action of the Ligand Antagonist Endogenous Drug? False

Interaction Types & Directionality: agonist (activating) antagonist (inhibitory)

Interaction Info:

Publications: Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy Gibson A et al., 1979, The effects of bromocriptine on pre-synaptic and post-synaptic alpha-adrenoceptors in the mouse vas deferens., J Pharm Pharmacol

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name bromocriptine mesylate,Cycloset, Ergoset Novel drug target Established target Specific Action of the Ligand Full agonist

Interaction Types & Directionality: agonist (activating)

Interaction Info: Specific Action of the Ligand Partial agonist Endogenous Drug? False

Publications: Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

Interaction Types & Directionality: agonist (activating)

Interaction Info: Specific Action of the Ligand Partial agonist Endogenous Drug? False

Publications: Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

Interaction Types & Directionality: antagonist (inhibitory) agonist (activating)

Interaction Info: Specific Action of the Ligand Antagonist Endogenous Drug? False

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Doknic et al., 2002, Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine., Eur. J. Endocrinol.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Figueroa et al., 1993, [Pharmacological modification of prolactinemia. Effects on cellular immune function in normal subjects]., Rev Med Chil

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Palestine et al., 1987, Bromocriptine and low dose cyclosporine in the treatment of experimental autoimmune uveitis in the rat., J. Clin. Invest.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Burdman et al., 2001, Bromocriptine and the expression of c-myc and c-fos in human prolactinomas., Neurol. Res.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Pelletier et al., 1991, Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus., Neurosci. Lett.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Orlowski et al., 1998, Bromocriptine modulates P-glycoprotein function., Biochem. Biophys. Res. Commun. Shiraki et al., 2002, Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells., Jpn. J. Cancer Res.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Lim et al., 2008, Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage., Pharmacol. Res.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Ohta et al., 2003, Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes., Life Sci.

Interaction Types & Directionality: n/a

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Partial agonist

Publications:

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Specific Action of the Ligand Antagonist

Endogenous Drug? False

Direct Interaction? True

Publications:

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Publications:

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Interaction Types & Directionality:

agonist (activating)

Publications:

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

Interaction Types & Directionality:

antagonist (inhibitory)

agonist (activating)

Interaction Info:

Endogenous Drug? False

Specific Action of the Ligand Antagonist

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Partial agonist

Endogenous Drug? False

Publications:

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Partial agonist

Endogenous Drug? False

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Partial agonist

Endogenous Drug? False

Publications:

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Partial agonist

Endogenous Drug? False

Interaction Types & Directionality:

antagonist (inhibitory)

Publications:

Knight et al., 2009, Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists., Mol. Pharmacol.

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Publications:

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

Gibson A et al., 1979, The effects of bromocriptine on pre-synaptic and post-synaptic alpha-adrenoceptors in the mouse vas deferens., J Pharm Pharmacol

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Specific Action of the Ligand Antagonist

Endogenous Drug? False

Interaction Types & Directionality:

antagonist (inhibitory)

agonist (activating)

Interaction Info:

Specific Action of the Ligand Antagonist

Endogenous Drug? False

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Publications:

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

Gibson A et al., 1979, The effects of bromocriptine on pre-synaptic and post-synaptic alpha-adrenoceptors in the mouse vas deferens., J Pharm Pharmacol

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name bromocriptine mesylate,Cycloset, Ergoset

Novel drug target Established target

Specific Action of the Ligand Full agonist

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Partial agonist

Endogenous Drug? False

Publications:

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Partial agonist

Endogenous Drug? False

Publications:

Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem

Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy

Interaction Types & Directionality:

antagonist (inhibitory)

agonist (activating)

Interaction Info:

Specific Action of the Ligand Antagonist

Endogenous Drug? False

Interaction Types & Directionality:

n/a

Publications:

Doknic et al., 2002, Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine., Eur. J. Endocrinol.

Interaction Types & Directionality:

n/a

Publications:

Figueroa et al., 1993, [Pharmacological modification of prolactinemia. Effects on cellular immune function in normal subjects]., Rev Med Chil

Interaction Types & Directionality:

n/a

Publications:

Palestine et al., 1987, Bromocriptine and low dose cyclosporine in the treatment of experimental autoimmune uveitis in the rat., J. Clin. Invest.

Interaction Types & Directionality:

n/a

Publications:

Burdman et al., 2001, Bromocriptine and the expression of c-myc and c-fos in human prolactinomas., Neurol. Res.

Interaction Types & Directionality:

n/a

Publications:

Pelletier et al., 1991, Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus., Neurosci. Lett.

Interaction Types & Directionality:

n/a

Publications:

Orlowski et al., 1998, Bromocriptine modulates P-glycoprotein function., Biochem. Biophys. Res. Commun.

Shiraki et al., 2002, Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells., Jpn. J. Cancer Res.

Interaction Types & Directionality:

n/a

Publications:

Lim et al., 2008, Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage., Pharmacol. Res.

Interaction Types & Directionality:

n/a

Publications:

Ohta et al., 2003, Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes., Life Sci.

Interaction Types & Directionality:

n/a

Publications:

Wynalda et al., 1997, Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen., Drug Metab. Dispos.

Interaction Types & Directionality:

n/a

Publications:

Burdman et al., 2001, Bromocriptine and the expression of c-myc and c-fos in human prolactinomas., Neurol. Res.

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Alternate Names:

BROMOCRIPTINE DrugBank Drug Name

25614-03-3 CAS Number

Apo-Bromocriptine Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Alternate Names:

BROMOCRIPTINE Primary Drug Name

Drug Info:

Year of Approval 1978

Drug Class antiparkinson agents

Drug Info:

Drug Indications antidiabetic

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

C317 NCI drug code